Novel evidence-based systemic lupus erythematosus responder index

Richard A. Furie, Michelle Petri, Daniel J. Wallace, Ellen M. Ginzler, Joan T. Merrill, William Stohl, W. Winn Chatham, Vibeke Strand, Arthur Weinstein, Marc R. Chevrier, Z. John Zhong, William W. Freimuth

Research output: Contribution to journalArticle

Abstract

Objective. To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. Methods. Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56-week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies ≥1:80 and/or anti-double-stranded DNA antibodies ≥30 IU/ml) at baseline was retrospectively evaluated using the SRI. Results. SRI response is defined as 1) a ≥4-point reduction in SELENA-SLEDAI score, 2) no new BILAG A or no more than 1 new BILAG B domain score, and 3) no deterioration from baseline in the physician's global assessment by ≥0.3 points. In serologically active patients, the addition of belimumab to SOC resulted in a response in 46% of patients at week 52 compared with 29% of the placebo patients (P = 0.006). SRI responses were independent of baseline autoantibody subtype. Conclusion. This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.

Original languageEnglish (US)
Pages (from-to)1143-1151
Number of pages9
JournalArthritis Care and Research
Volume61
Issue number9
DOIs
StatePublished - Sep 15 2009

Fingerprint

Systemic Lupus Erythematosus
Placebos
Standard of Care
Estrogens
Safety
Antinuclear Antibodies
Health Surveys
Autoantibodies
Therapeutics
Randomized Controlled Trials
Biomarkers
Clinical Trials
Physicians
Antibodies
DNA
belimumab

ASJC Scopus subject areas

  • Rheumatology

Cite this

Furie, R. A., Petri, M., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., ... Freimuth, W. W. (2009). Novel evidence-based systemic lupus erythematosus responder index. Arthritis Care and Research, 61(9), 1143-1151. https://doi.org/10.1002/art.24698

Novel evidence-based systemic lupus erythematosus responder index. / Furie, Richard A.; Petri, Michelle; Wallace, Daniel J.; Ginzler, Ellen M.; Merrill, Joan T.; Stohl, William; Chatham, W. Winn; Strand, Vibeke; Weinstein, Arthur; Chevrier, Marc R.; Zhong, Z. John; Freimuth, William W.

In: Arthritis Care and Research, Vol. 61, No. 9, 15.09.2009, p. 1143-1151.

Research output: Contribution to journalArticle

Furie, RA, Petri, M, Wallace, DJ, Ginzler, EM, Merrill, JT, Stohl, W, Chatham, WW, Strand, V, Weinstein, A, Chevrier, MR, Zhong, ZJ & Freimuth, WW 2009, 'Novel evidence-based systemic lupus erythematosus responder index', Arthritis Care and Research, vol. 61, no. 9, pp. 1143-1151. https://doi.org/10.1002/art.24698
Furie RA, Petri M, Wallace DJ, Ginzler EM, Merrill JT, Stohl W et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Care and Research. 2009 Sep 15;61(9):1143-1151. https://doi.org/10.1002/art.24698
Furie, Richard A. ; Petri, Michelle ; Wallace, Daniel J. ; Ginzler, Ellen M. ; Merrill, Joan T. ; Stohl, William ; Chatham, W. Winn ; Strand, Vibeke ; Weinstein, Arthur ; Chevrier, Marc R. ; Zhong, Z. John ; Freimuth, William W. / Novel evidence-based systemic lupus erythematosus responder index. In: Arthritis Care and Research. 2009 ; Vol. 61, No. 9. pp. 1143-1151.
@article{60576e1e100047d79c4882141ef953fc,
title = "Novel evidence-based systemic lupus erythematosus responder index",
abstract = "Objective. To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. Methods. Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56-week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies ≥1:80 and/or anti-double-stranded DNA antibodies ≥30 IU/ml) at baseline was retrospectively evaluated using the SRI. Results. SRI response is defined as 1) a ≥4-point reduction in SELENA-SLEDAI score, 2) no new BILAG A or no more than 1 new BILAG B domain score, and 3) no deterioration from baseline in the physician's global assessment by ≥0.3 points. In serologically active patients, the addition of belimumab to SOC resulted in a response in 46{\%} of patients at week 52 compared with 29{\%} of the placebo patients (P = 0.006). SRI responses were independent of baseline autoantibody subtype. Conclusion. This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.",
author = "Furie, {Richard A.} and Michelle Petri and Wallace, {Daniel J.} and Ginzler, {Ellen M.} and Merrill, {Joan T.} and William Stohl and Chatham, {W. Winn} and Vibeke Strand and Arthur Weinstein and Chevrier, {Marc R.} and Zhong, {Z. John} and Freimuth, {William W.}",
year = "2009",
month = "9",
day = "15",
doi = "10.1002/art.24698",
language = "English (US)",
volume = "61",
pages = "1143--1151",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Novel evidence-based systemic lupus erythematosus responder index

AU - Furie, Richard A.

AU - Petri, Michelle

AU - Wallace, Daniel J.

AU - Ginzler, Ellen M.

AU - Merrill, Joan T.

AU - Stohl, William

AU - Chatham, W. Winn

AU - Strand, Vibeke

AU - Weinstein, Arthur

AU - Chevrier, Marc R.

AU - Zhong, Z. John

AU - Freimuth, William W.

PY - 2009/9/15

Y1 - 2009/9/15

N2 - Objective. To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. Methods. Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56-week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies ≥1:80 and/or anti-double-stranded DNA antibodies ≥30 IU/ml) at baseline was retrospectively evaluated using the SRI. Results. SRI response is defined as 1) a ≥4-point reduction in SELENA-SLEDAI score, 2) no new BILAG A or no more than 1 new BILAG B domain score, and 3) no deterioration from baseline in the physician's global assessment by ≥0.3 points. In serologically active patients, the addition of belimumab to SOC resulted in a response in 46% of patients at week 52 compared with 29% of the placebo patients (P = 0.006). SRI responses were independent of baseline autoantibody subtype. Conclusion. This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.

AB - Objective. To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. Methods. Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56-week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies ≥1:80 and/or anti-double-stranded DNA antibodies ≥30 IU/ml) at baseline was retrospectively evaluated using the SRI. Results. SRI response is defined as 1) a ≥4-point reduction in SELENA-SLEDAI score, 2) no new BILAG A or no more than 1 new BILAG B domain score, and 3) no deterioration from baseline in the physician's global assessment by ≥0.3 points. In serologically active patients, the addition of belimumab to SOC resulted in a response in 46% of patients at week 52 compared with 29% of the placebo patients (P = 0.006). SRI responses were independent of baseline autoantibody subtype. Conclusion. This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.

UR - http://www.scopus.com/inward/record.url?scp=69749096135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69749096135&partnerID=8YFLogxK

U2 - 10.1002/art.24698

DO - 10.1002/art.24698

M3 - Article

C2 - 19714615

AN - SCOPUS:69749096135

VL - 61

SP - 1143

EP - 1151

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 9

ER -